Drugs / Sm-p80
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05292391 | May 2022 → Mar 2024 | schistosomiasis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05999825 | Sep 2024 → Apr 2025 | Schistosoma mansoni infectious disease | Leiden University Medical Center | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sm-p80 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05292391 ↗ |
| Modality | Protein / enzyme biologic | “The Sm-p80 protein is formulated and lyophilized to yield the vaccine antigen, Sm-p80 for Injection.” NCT05292391 ↗ |
| Route | Intramuscular | “0.5 mL of 100 micrograms of Sm-p80 administered intramuscularly on Days 1, 29, and 57.” NCT05292391 ↗ |